Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 14,134 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Cystic Fibrosis
Interventions: PTI-428, Placebo; Drug
Lead sponsor: Proteostasis Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 26
States / cities: Birmingham, Alabama • Tucson, Arizona • Stanford, California + 21 more

Conditions: Moderate to Severe Acute Lower Back Pain
Interventions: SP-103, Placebo; Drug
Lead sponsor: Scilex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 10
States / cities: Phoenix, Arizona • Fernandina Beach, Florida • Jacksonville, Florida + 7 more

Conditions: Hayfever, Rhinitis, Allergic, Seasonal, Seasonal Allergic Rhinitis
Interventions: fluticasone furoate; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 4
States / cities: Austin, Texas • New Braunfels, Texas • San Antonio, Texas

Conditions: Healthy Volunteers
Interventions: Purified Inactivated Zika Virus Vaccine (PIZV), Placebo; Biological · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 49 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 5
States / cities: Oakland Park, Florida • Meridian, Idaho • Wichita, Kansas + 2 more

Conditions: Schizophrenia
Interventions: Inhaled Placebo, Inhaled Loxapine 5 mg, Inhaled Loxapine 10 mg; Drug
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Upland, California

Conditions: Healthy Volunteer
Interventions: DISC-3405, Placebo; Drug
Lead sponsor: Disc Medicine, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Cardiovascular Disease
Interventions: Febuxostat, Allopurinol; Drug
Lead sponsor: Takeda; Industry
Eligibility: 50 Years and older
Enrollment: 6,198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 202
States / cities: Decatur, Georgia • Dunwoody, Georgia • Marietta, Georgia + 199 more

Conditions: Sleep Problem, Behavior, Child
Interventions: Sleep Health in Preschoolers (SHIP), Family Check-Up (FCU), Oral Health, Child Safety, and Environmental Health Intervention (Active Control); Behavioral
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Months to 48 Months
Enrollment: 305 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Denver, Colorado • Boston, Massachusetts

Conditions: Scar Prevention
Interventions: EXC 001, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Chicago, Illinois • St Louis, Missouri

Conditions: Progressive Supranuclear Palsy
Interventions: Davunetide, Placebo; Drug
Lead sponsor: Allon Therapeutics; Industry
Eligibility: 41 Years to 85 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more

Conditions: Diabetic Nephropathy
Interventions: Nidufexor, Placebo, Standard of Care (SoC); Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Miami Lakes, Florida • Albany, New York • Norman, Oklahoma + 2 more

Conditions: HIV Infections
Interventions: Tenofovir disoproxil fumarate; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • Seattle, Washington

Conditions: Impaired Glucose Tolerance, Insulin Resistance
Interventions: LIM-0705, Placebo capsules; Drug
Lead sponsor: Limerick BioPharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Hallux Valgus, Bunionectomy
Interventions: ALX006 (bupivacaine extended-release injection), Bupivacaine Hcl 0.25% Inj, Sciatic Nerve Block; Drug · Procedure
Lead sponsor: Rebel Medicine Inc; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Millcreek, Utah

Conditions: Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
Interventions: Belimumab, Placebo; Biological · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 25
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more

Conditions: Clostridioides Difficile Infection
Interventions: AZD5148, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 43
States / cities: Phoenix, Arizona • Chula Vista, California • Sacramento, California + 39 more

Conditions: Early Alzheimer's Disease
Interventions: Experimental: ALZ-801, Placebo Comparator: Placebo; Drug
Lead sponsor: Alzheon Inc.; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 55
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 50 more

Conditions: Retinopathy of Prematurity (ROP)
Interventions: myo-Inositol 5% Injection, Placebo; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 12 Hours to 72 Hours
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more

Conditions: Spondyloarthritis
Interventions: Ixekizumab, Placebo, Adalimumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 19
States / cities: Phoenix, Arizona • Huntington Beach, California • Palm Desert, California + 16 more

Conditions: Dermatitis, Atopic Dermatitis
Interventions: Apremilast, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 15
States / cities: Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 10 more

Conditions: Generalized Tonic Clonic Seizures
Interventions: Pregabalin Dose Level 1, Pregabalin Dose Level 2, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 5 Years to 65 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 12
States / cities: Loxahatchee Groves, Florida • Orlando, Florida • Port Charlotte, Florida + 6 more

Conditions: Opioid Dependency
Interventions: Probuphine (buprenorphine implant), placebo implant, Buprenorphine; Drug
Lead sponsor: Titan Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 20
States / cities: Los Angeles, California • National City, California • Oceanside, California + 16 more

Conditions: Human Immunodeficiency Virus Type 1
Interventions: D/C/F/TAF, Boosted Protease Inhibitor (bPI), FTC/TDF; Drug
Lead sponsor: Janssen R&D Ireland; Industry
Eligibility: 18 Years and older
Enrollment: 1,149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 38
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 35 more

Conditions: Patent Ductus Arteriosus, Preterm Infant, Bronchopulmonary Dysplasia
Interventions: Ibuprofen and acetaminophen, Ibuprofen and placebo; Drug
Lead sponsor: University of South Alabama; Other
Eligibility: 5 Days to 21 Days
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Mobile, Alabama

Search by objective public record fields.

Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis

Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain

Study In Adults And Adolescents With Seasonal Allergic Rhinitis

A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults

Staccato Loxapine in Agitation (Proof of Concept)

A Study of DISC-3405 in Healthy Volunteers

Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)

Parents Advancing Toddler Health

Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty

Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy

The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients

Safety, Tolerability, PK, and PD of LIM-0705 in Subjects With Impaired Glucose Tolerance or Abnormal HOMA-IR

Sciatic Nerve Block With ALX006 in Subjects Undergoing Bunionectomy

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

Inositol to Reduce Retinopathy of Prematurity

A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis

Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis

A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.

A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

Randomized Controlled Trial to Evaluate the Safety and Efficacy of Acetaminophen in Preterm Infants Used in Combination With Ibuprofen for Closure of the Ductus Arteriosus